August 6, 2009 – Palatin Technologies Inc. said this week it received a notice of allowance from the U.S. Patent and Trademark Office covering a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, which is Palatin's lead heart failure drug candidate.

August 6, 2009 – Merck & Co. Schering-Plough Corp. and the companies' cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals (MSP), this week announced they entered into agreements to resolve class-action litigation currently pending against the companies relating to the purchase or use of VYTORIN and ZETIA.

August 5, 2009 – The Society of Cardiovascular Computed Tomography (SCCT) named Chirapa Puntawangkoon, M.D., and Thananya Boonyasirinant, M.D., the winners of the third annual Young Investigator Award.

Both winners were honored at SCCT’s 2009 Annual Scientific Meeting in Orlando, Fla.

August 45, 2009 – Featherstone Informatics Group Inc. (FIG) this week said it was chosen as the exclusive vendor for the American College of Cardiology's practice-based quality improvement program, called the IC3 Program (Improving Continuous Cardiac Care).

August 5, 2009 – Stereotaxis Inc. said today clinicians performed more than 2,500 procedures with the magnetic irrigated catheter since its commercial release, and the major adverse cardiac event (MACE) rate for magnetic procedures remains at 0.1 percent.

August 5, 2009 – Nile Therapeutics Inc. said this week it dosed its first patient in a phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

August 4, 2009 – Watson Pharmaceuticals Inc. said this week it received FDA approval on its abbreviated new drug applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths, which are the generic equivalent to AstraZeneca's Toprol XL tablets.

August 3, 2009 – Kowa Research Institute (KRI) and Kowa Pharmaceuticals America Inc. (KPA) said today the FDA has cleared LIVALO (pitavastatin), a potent HMG-CoA reductase inhibitor (statin) for the primary treatment of hypercholesterolemia and combined dyslipidemia.

The company said the drug offers a new therapeutic option to a large, competitive market for cardiometabolic disorders.

August 3, 2009 – IDEAL LIFE Inc. said today its wireless remote monitoring devices were selected for a state-funded healthcare project to home monitor heart failure patients in six rural North Carolina communities.

August 4, 2009 – The Yale University School of Medicine today announced the successful enrollment of more than 1,650 heart failure (HF) patients as part of the National Institutes of Health (NIH)-sponsored, Tele-HF study to evaluate the impact of device-free remote patient monitoring (RPM) on improving chronic care management and reducing hospitalizations of HF patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now